Mirikizumab Biosimilar - Research Grade

Human

IL23A

>1mg/ml

IgG4 - kappa

CHO Cells

Guselkumab Biosimilar - Research Grade (ICH5064), Risankizumab Biosimilar - Research Grade (ICH5210), Tildrakizumab Biosimilar - Research Grade (ICH5303), Brazikumab Biosimilar - Research Grade (ICH5413), Picankibart Biosimilar - Research Grade (ICH5772)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NPF7

51561

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of mirikizumab, a humanized IgG4-kappa monoclonal antibody directed against the p19 subunit of interleukin-23 (encoded by IL23A). It is manufactured for research use only and is not the clinical drug; it is not intended for human or veterinary use. The analog reproduces the target-binding specificity of the originator, making it a useful reference reagent for benchtop and preclinical work: as a positive/isotype-matched control in binding assays, for IL-23 neutralization studies, for pathway interrogation in cell-based systems, and as a comparator or building block in antibody-engineering and ADC-development workflows. Because it is supplied unconjugated, users can label, format, or otherwise adapt it to their assay. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support in-vitro assay development, screening cascades, and preclinical in-vivo standard-setting. This description is provided for ichorbio to review and is intended as educational guidance around the target rather than clinical claims. IL23A encodes the p19 subunit of interleukin-23, a heterodimeric cytokine formed when p19 pairs covalently with the p40 subunit (IL12B) that is shared with IL-12. IL-23 signals through a receptor complex of IL23R and IL12RB1, activating JAK2/TYK2 and predominantly STAT3. It is a key driver of the type-17 immune axis: IL-23 stabilizes and expands pathogenic Th17 cells and stimulates innate lymphoid and gamma-delta T cells to produce IL-17, IL-22, and GM-CSF. This p19-dependent activity sustains chronic mucosal and skin inflammation, underpinning its role in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Antibodies targeting p19 selectively block IL-23 while sparing IL-12, distinguishing them from p40-directed agents.

IL-23 subunit alpha, Interleukin-23 subunit p19, IL-23p19, Interleukin-23 subunit alpha, SGRF

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Mirikizumab (anti-IL23A) Biosimilar

Q: Is the Mirikizumab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Mirikizumab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Mirikizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Mirikizumab that binds IL23A; for research use only.